OvaScience (OVAS) Reaches OvaPrime and OvaTure Goals for 2015; Offers Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
OvaScience Provides Business Update and Outlines 2015 Corporate Progress
December 7, 2015 4:30 PM EST- Company Achieves 2015 OvaPrime and OvaTure Treatment Goals -
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the Company has achieved its 2015 corporate goals for the OvaPrimeSM and OvaTureSM fertility treatments.
OvaPrime Treatment Preceptorship Program OvaScience commenced a non-commercial preceptorship program with the OvaPrime treatment at an in vitro fertilization (IVF) clinic outside of the United States to gain insight into the clinical efficacy and... More